The neuroendocrine effects of venlafaxine in healthy subjects

Human Psychopharmacology

Volumn 11, Issue 1, 1996, Pages 1-9

  Daffner Bugia C ^a   Laakmann, G ^a   Voderholzer, U ^a   Haag, C ^a   Baghai, T ^a   Kolmsee, S ^a   Schroder U ^a   Munz, T ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Wyeth Pharma GmbH   (Germany)

Author keywords

Anterior pituitary hormones; Reuptake inhibition; Venlafaxine

Indexed keywords

CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; GROWTH HORMONE; HYDROCORTISONE; NOMIFENSINE; NORADRENALIN; PLACEBO; PROLACTIN; SEROTONIN; VENLAFAXINE;

ADRENERGIC SYSTEM; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUROENDOCRINOLOGY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN RELEASE; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYNAPTOSOME; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

EID: 0030062804     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199601)11:1<1::AID-HUP732>3.3.CO;2-Q     Document Type: Article

References (28)

1. Boyd, A. D., Lebowitz, H. E. and Pfeiffer, J. B. (1970). Stimulation of human-growth-hormone secretion by L-dopa. New England Journal of Medicine, 283, 1425-1429.
2. Brown, W. A. and Williams, B. W. (1976). Methyl-phenidate increases serum growth hormone concentrations. Journal of Clinical Endocrinology and Metabolism, 43, 937-939.
3. Hyttel, J. (1982). Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progressions of Neuropsychopharmacology and Biological Psychiatry, 6, 277-295.
4. Imura, H., Nakai, K. and Yoshimi, T. (1973). Effect of 5-hydroxytryptophan (5-HT-P) on growth hormone and ACTH release in man. Journal of Clinical Endocrinology and Metabolism, 36, 204-206.
5. Khan, A., Fabre, L. F. and Rudolph, R. (1991). Venlafaxine in depressed outpatients. Psychopharmacology Bulletin, 27, 141-144.
6. Kleinberg, D. L., Noel, G. L. and Frantz, A. G. (1971). Chlorpromazine stimulation and L-dopa suppression of plasma prolactin in man. Journal of Clinical Endocrinology and Metabolism, 33, 873-876.
7. Laakmann, G. (1990). Psychopharmacology and Depression Research, Springer Verlag, Berlin, Heidelberg, New York.
8. Laakmann, G., Schuhmacher, G., Benkert, O. and von Werder, K. (1977). Stimulation of growth hormone secretion by desimipramine and chlorimipramine in man. Journal of Clinical Endocrinology and Metabolism, 44, 1010-1013.
9. Laakmann, G., Guillery, T., Benkert, O. and Eversmann, T. (1979). Influence of nomifensine on growth hormone, prolactin, luteinising hormone and thyreotropin in healthy subjects and hyperprolacinaemic patients. In: Biological Psychiatry Today. Proceedings of the II World Congress on Biological Psychiatry, 1978, Obiols, J., Ballus, C., Monclus, E. G. and Pujol, J. (Eds), Elsevier-North Holland, Amsterdam, New York, Oxford, pp. 705-710.
10. Laakmann, G., Schön, H. W. and Wittmann, M. (1981). Desipramine and growth hormone secretion. Lancet, ii, 996.
11. Laakmann, G., Gugath, M., Kuss, H. J. and Zygan, K. (1984a). Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Psychopharmacology, 82, 62-67.
12. Laakmann, G., Wittmann, M., Gugath, M., Müller, O. A., Treusch, J., Wahlster. U. and Stella, G. K. (1984b). Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride, and diazepam) on the human HPA axis. Psychopharmacology, 84, 66-70.
13. Laakmann, G., Wittmann, M., Neulinger, E. and Meissner, R. (1984c). Effects of psychotropic drugs on neuroendocrine regulation of pituitary hormones in man. In: Clinical Neuropharmacology, Vol. 7. Racagni, G., Paoletti, R. and Kielholz, P. (Eds), Raven Press, New York, pp. 156-157.
14. Laakmann, G., Schön, H. W., Blaschke, D. and Wittmann, M. (1985). Dose-dependent growth hormone, prolactin and cortisol stimulation after i.v. administration of desimipramine in human subjects. Psychoneuroendocrinology, 10, 83-93.
15. Laakmann, G., Wittmann, M., Schön, H. W., Weiss, A., Wittmann, M. and Meissner, R. (1986). Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosine) on desimipramine-induced pituitary hormone stimulation in humans. III: Hypothalamo-pituitary-adrenocortical axis. Psychoneuroendocrinology, 11, 475-489.
16. Lal, S., Tolis, G., Martin, J. B., Brown, G. M. and Guyda, H. (1975). Effect of clonidine on growth hormone, prolactin, luteinizing hormone, folliclestimulating hormone and thyroid-stimulating hormone in the serum. Journal of Clinical Endocrinology and Metabolism, 41, 827-832,
17. MacIndoe, J. H. and Turkington, R. W. (1973). Stimulation of human prolactin secretion by intravenous infusion of L-tryptophan. Journal of Clinical Investigation, 52, 1972-1978.
18. MacLeod, R. M. (1976). Regulation of prolactin secretion. In: Frontiers in neuroendocrinology, Vol. 4, Ganong, W. F. and Martini, L. (Eds), Elsevier, New York, pp. 169-194.
19. Martin, J. B. and Reichlin, S. (1987). Clinical Neuroendocrinology, 2nd edn. Davis, Philadelphia.
20. Meltzer, H. Y., Piyakalmala, S., Schyve, P. and Fang, V. S. (1977). Lack of effect of tricyclic antidepressants on serum prolactin levels. Psychopharmacology, 51, 185-187.
21. Moyer, J. A., Andree, T. H., Haskins, J. T., Husbands, G. M. S. and Muth, E. A. (1992). The preclinical pharmacological profile of venlafaxine: a novel antidepressant agent. CNS Division, Wyeth-Ayerst Research.
22. Muth, A. E., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T. and Sigg, E. B. (1986). Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology, 35, 4493-4497.
23. Nakai, Y., Imura, H., Yoshima, T. and Matsukura, S. (1973). Adrenergic control mechanism for ACTH secretion in man. Acta Endocrinologica, 74, 263-270.
24. Nutt, D., Middleton, H. and Franklin, M. (1987). The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology, 12, 367-375.
25. Pozo, E. del and Lancranjan, I. (1978). Clinical use of drugs modifying the release of anterior pituitary hormones. In: Frontiers in Neuroendocrinology. Vol. 5, Ganong, W. F. and Martini, L. (Eds), Elsevier, New York, pp. 207-247.
26. Quattrone, A., Tedeschi, G., Aguglia, U., Scopacas, F., di Landro, G. H. and Annunziatom, L. (1983). Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurons. Studies with fenfluramine. British Journal of Clinical Pharmacology. 16, 471-475.
27. Schweizer, E., Weise, C., Clary, C., Fox, I. and Rickels, K. (1991). Placebo-controlled trial of venlafaxine for the treatment of major depression. Journal of Clinical Psychopharmacology, 11, 233-236.
28. Wirz-Justice, A., Pühringer, W., Lacoste, V., Graw, P., Gastpar, P. and Gastpar, M. (1976). Intravenous L-5-hydroxytryptophan in normal subjects: an interdisciplinary precursor study. Pharmacopsychiatry, 9, 277-288.